Pfizer Independent Medical Education Grant Request for Proposals

Competitive Grant Program – Pfizer Internal Review Process

Closing Knowledge Gaps and Building Practical Skills in HRRm Testing for Metastatic Prostate Cancer

Overview

This competitive grant program seeks to fund high-impact Independent Medical Education (IME) initiatives designed to address critical knowledge, skill, and confidence gaps among healthcare professionals (HCPs) regarding Homologous Recombination Repair mutation (HRRm) testing in metastatic prostate cancer (mPC).

The goal of this RFP is to move beyond foundational knowledge and equip the multidisciplinary team with the practical skills needed to support guideline-based HRRm testing across the patient care pathway. This includes a deep focus on the pre-analytical phase, where specimen-related factors may affect testing feasibility and quality, as well as advanced skills in interpreting, communicating and applying HRRm testing information in clinical practice. Projects should prioritize educational interventions that equip HCPs with knowledge, competencies, and confidence needed to evaluate and apply guideline-recommended HRRm testing approaches in clinical practice. Proposals should demonstrate measurable impact on learner knowledge, competence, and confidence in testing-related decision-making, multidisciplinary collaboration, and application of guideline-based testing pathways.

Geographic Scope

Global (ex-US) with priority in Europe (France, Germany, Italy, Spain, United Kingdom), Asia-Pacific region (Australia and China)

Project Types and Area of Interest

A key priority of this RFP is bridging the academic-community practice gap. Programs that provide practical educational resources, case-based learning, best-practice considerations in HRRm testing from specimen acquisition through biomarker-informed treatment decision-making, or educational frameworks that support HCPs in applying evidence-based testing recommendations in routine clinical practice are particularly encouraged. Proposals should be comprehensive and address topics across the following key educational domains:

- *Domain 1: Pre-Analytical and Multidisciplinary Considerations Across the HRRm Testing Pathway*
- *Domain 2: Clinical Rationale and Guideline-Based Considerations for HRRm Testing*
- *Domain 3: Applying and Communicating HRRm Testing Results in Clinical Practice*

Key Milestones

Funding Range and Project Length

Total available budget related to this RFP is approximately $300,000.00.

Individual projects covering multiple countries requesting up to $100,000 will be considered. Smaller projects are also encouraged (e.g. $30,000-$50,000).

Maximum project length is 12 months.

I. Eligibility

Geographic Scope/Location of Project:

- Global (ex-US) with priority in Europe (France, Germany, Italy, Spain, United Kingdom), Asia-Pacific region (Australia and China)

Applicant Eligibility Criteria

- The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead's grant coordinator).
- The project/program lead must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.
- For projects offering continuing education credit, the requesting organization must be accredited.
- For Italy only, *Educazione Continua in Medicina* (ECM) events will not be supported. Only non-ECM initiatives will be evaluated.

II. Requirements

Primary Area of Interest:

- Oncology – Genitourinary - IME

General Area of Interest for this RFP:

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

A key priority of this RFP is bridging the academic-community practice gap. Programs that provide practical educational resources, case-based learning, best-practice considerations in HRRm testing from specimen acquisition through biomarker-informed treatment decision-making, or educational frameworks that support HCPs in applying evidence-based testing recommendations in routine clinical practice are particularly encouraged. Proposals focused primarily on therapeutic sequencing, product-specific efficacy discussions, or treatment selection education are outside the primary scope. Proposals should be comprehensive and address topics across the following key educational domains:

Domain 1: Pre-Analytical and Multidisciplinary Considerations Across the HRRm Testing Pathway

This domain focuses on providing multidisciplinary education on key considerations across the testing pathway, from sample acquisition to final report, to support appropriate and effective HRRm testing practices.

- Understanding the HRRm testing pathway: Education that maps the entire testing pathway, identifying key steps, responsibilities, and potential failure points. Educational programs that teach clinicians how to recognize and proactively avoid common testing failures, delays, and communication challenges encountered during routine clinical practice.
- Multidisciplinary Team Education for Guideline-Concordant Testing Initiation: Educational initiatives designed to strengthen multidisciplinary understanding of roles, responsibilities, and coordination across the HRRm testing pathway, with a focus on promoting timely and guideline-informed initiation of testing. Programs may include case-based discussions that illustrate how urologists, medical oncologists, pathologists, genetic counselors, nurses, and other members of the care team contribute to appropriate testing decisions and longitudinal patient management.
- Specimen selection considerations: Education on appropriate specimen selection strategies, including considerations for tissue- and blood-based testing approaches, factors affecting sample adequacy, and common causes of testing failure or delays.
- Educational initiatives may also address earlier testing-pathway touchpoints relevant to specimen acquisition, testing readiness, and patient communication when relevant to understanding the patient journey and preparing for potential future HRRm testing in mPC.
- Collaborative Education on Biopsy and Specimen Handling Consideration at the Pre-analytical Phase:
    - For Urologists/Interventional Radiologists: Education on biopsy-related considerations relevant to obtaining adequate tissue for successful HRRm molecular testing, including critical sample handling procedures. This should address common points of failure such as the impact of decalcification methods on nucleic acid quality for bone biopsies and other pre-analytical nuances that differ from standard histopathological preparation.
    - For Pathologists/Lab Staff: education on decalcification methods and their potential impact on molecular testing quality, handling of blocks and slides, and the role of macrodissection in tumor enrichment.
    - Education on urology–pathology communication considerations, including factors that may affect specimen handling, sample integrity, and testing readiness.

Domain 2: Clinical Rationale and Guideline-Based Considerations for HRRm Testing

- Understanding HRR Gene Mutations:
    - Context and Definition: Clarify that BRCA1/2 are key but are part of a broader family of HRR genes. Address variation in HRRm panel composition and discuss relevant guideline-based considerations.
    - Epidemiology and Prognosis: Educate on the frequency of HRRm alterations across different prostate cancer settings (e.g., mHSPC vs. mCRPC) and the prognostic implications of an HRRm-positive disease state.
    - Therapeutic and Hereditary Impact: Explain the clinical implications of HRRm status, including its impact on treatment decision-making and hereditary cancer risk assessment. Educational initiatives are encouraged to use case-based learning approaches that help clinicians identify

appropriate candidates for testing, apply guideline-informed testing principles in realistic clinical scenarios, and recognize when multidisciplinary input may be beneficial.

- Addressing Common Misconceptions and Building Practical Algorithms: Create educational content that directly addresses common myths and perceived barriers to HRRm testing. This includes addressing the perception that testing has low relevance for practitioners not directly involved in therapy intensification by clearly illustrating how guideline-concordant testing initiated in their practice directly impacts the patient's long-term, multidisciplinary care pathway and future treatment options. Develop educational content that illustrates practical guideline-informed approaches to HRRm testing in mPC, suitable for both academic and community practice settings.

Domain 3: Applying and Communicating HRRm Testing Results in Clinical Practice

- Understanding the Genomic Report: Educate clinicians on the "anatomy of a genomic report" so they can confidently interpret key fields and findings related to HRRm.
- Case-Based Interpretation and Application of HRRm Results: Educational initiatives should use practical patient scenarios to strengthen clinician confidence in interpreting HRRm findings and applying testing information in routine practice.
    - Interactive learning focused on interpretation of HRRm genomic reports.
    - Educational exercises using real-world patient cases.
    - Understanding variant classifications, testing limitations, and practical interpretation challenges.
    - Case-based application of testing results within multidisciplinary care discussions.
- Upskilling for the Germline Testing Pathway: Develop accredited educational programs to strengthen non-genetics providers (urologists, oncologists, APPs, nurses) in the core competencies of confident pre-test counseling, test-ordering considerations, and effective collaboration with genetic counselors. Educational content should be consistent with local regulations and professional standards governing genetic testing and counseling.
- Strengthening Multidisciplinary and Patient Communication:
    - Provide education on how to effectively collaborate with genetic counselors for the interpretation of post-test results and management of germline findings.
    - Develop skills for effective patient counseling on HRR testing results and biomarker-informed treatment discussions to facilitate true shared decision-making.
- Examples of educational formats that will be considered under this RFP include but are not limited to:
    - On-agenda educational sessions during live conferences
    - Interactive report interpretation workshops
    - Case-based decision-making modules
    - Competency-based learning pathways
    - Multidisciplinary case conferences focused on HRRm testing
    - Multi-company supported, stand-alone symposia
    - Expert interviews recorded at live conferences, conference coverage reviews
    - Online articles, newsletter articles, training courses, webinars

- Social media posted & linked content
- Videos, podcasts, infographics, animations
- Creative educational initiatives with the potential for wide-reaching engagement
- Education using online platforms with downloadable resources and reference tools for HCPs and/or patients
- Interactive learnings, case-based learnings, workshops, tumor boards
- Curriculum-based series that are updated accordingly throughout grant lifecycle to reflect real-time data and evolving treatment landscape

Target Audience

- Medical oncologists, urologists, uro-oncologists, radiation oncologists, pathologists, nurses, physician assistants, pharmacists, genetic counselors, and other HCPs involved in the care, testing, and treatment decision-making of patients with metastatic prostate cancer.

Expected Approximate Monetary Range of Grant Applications

- Individual projects covering multiple countries requesting up to $100,000 will be considered. Smaller projects are also encouraged (e.g. $30,000-$50,000). The estimated total available budget related to this RFP is $300,000.00.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

Key Dates:



IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

- *Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5)
-

How to Submit:

IMPORTANT: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Click here to navigate to this Competitive Grant Program's unique Program Application Form: Login
  - First-time users should create a Requester Portal account by clicking **Not a member?**
- OR

- Navigate to: https://pfizermarcie.my.site.com/pfzrequester and sign in.
- In the upper navigation bar, click **Grant Programs** to see all available programs.
- Select Medical Education
- Click **Apply** on the **2026 ONC ExUS Metastatic Prostate Cancer** IME to open the Program Application Form.
- Requirements for submission:
  - Complete all required sections of the online application
  - **IMPORTANT:** Upload proposal (see Appendix) in the Proposal/Protocol field.
  - For more information on navigating Pfizer's new grant management system (MARCIE), please refer to this helpful User Guide.

Questions:

- Please click here to view "Frequently Asked Questions" regarding the Competitive Grant Program.
- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Nicola Fenderico (Nicola.Fenderico@Pfizer.com), with the subject line "Closing Knowledge Gaps and Building Practical Skills in HRRm Testing for Metastatic Prostate Cancer Sep 2026"

Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.
- For selected projects: Pfizer will support only those projects for which an executed copy of the Agreement, the Protocol, and documentation of IRB/IEC approval, regulatory approval (if applicable), exemption, or waiver have been received by **15 December 2026**.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.
- This RFP is supported by Pfizer Inc. and, if approved the payment will be issued by a Pfizer US based legal entity.

About Pfizer Grants

- Pfizer supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.
- Pfizer's competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an

internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

- For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

Appendix

IMPORTANT: RFP Submission Requirements

Applications will be accepted via the online portal listed in the How to Submit section. Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Project Proposal please ensure it addresses the following sections:

Goals and Objectives

- Briefly state the overall goal of the project.
- List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

Assessment of Need for the Project

- Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

Target Audience

- Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

Project Design and Methods

- Describe the planned project, the educational approach, and the way the planned methods address the established need.

Innovation

- Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.

Evaluation and Outcomes

- In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data.
- Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms of the target audience. Describe how your organization will determine if the target audience was fully engaged in the project. Applicants are encouraged to measure educational outcomes using validated approaches assessing knowledge, competence, confidence, intended practice change, learner engagement

Dissemination Plan

- Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

Organization Detail

- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

Budget Detail

- Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application.
- While estimating your budget please keep the following items in mind:
- Independent Medical Education Grants awarded by GMGP cannot be used to purchase therapeutic assets (prescription or non-prescription).
- Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer. Please click here for details. General organizational running costs such as legal fees, insurance, heating and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.

Required Documents

- Project Plan/Proposal or Meeting Agenda